"rAF" neighborhood: Protein-protein interaction in the Raf/Mek/Erk pathway

FEBS Letters

Volumn 588, Issue 15, 2014, Pages 2398-2406

  Cseh, Botond ^a   Doma, Eszter ^a   Baccarini, Manuela ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cancer therapy; Erk; Kinase inhibitor; Mek; Protein protein interaction; Raf; Ras

Indexed keywords

2 [4 (1 HYDROXYIMINO 5 INDANYL) 3 (4 PYRIDINYL) 1H PYRAZOL 1 YL]ETHANOL; CH 5126766; DABRAFENIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PROTEIN INHIBITOR; RAF PROTEIN; RAS PROTEIN; SELUMETINIB; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB;

CELL PROLIFERATION; GENE MUTATION; GENETIC CONSERVATION; HUMAN; KERATOACANTHOMA; MELANOMA; METASTATIC MELANOMA; MOLECULAR INTERACTION; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAF MEK ERK SIGNALING PATHWAY; REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SKIN TOXICITY;

CANCER THERAPY; ERK; KINASE INHIBITOR; MEK; PROTEIN-PROTEIN INTERACTION; RAF; RAS;

ANIMALS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROTEIN BINDING; RAF KINASES;

EID: 84904252088     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2014.06.025     Document Type: Review

References (141)

1. T.S. Niault, and M. Baccarini Targets of Raf in tumorigenesis Carcinogenesis 31 2010 1165 1174
2. D. Vigil, J. Cherfils, K.L. Rossman, and C.J. Der Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nat. Rev. Cancer 10 2010 842 857
3. R. Roskoski Jr. MEK1/2 dual-specificity protein kinases: structure and regulation Biochem. Biophys. Res. Commun. 417 2012 5 10
4. R. Roskoski Jr. ERK1/2 MAP kinases: structure, function, and regulation Pharmacol. Res. 66 2012 105 143
5. D.T. Leicht, V. Balan, A. Kaplun, V. Singh-Gupta, L. Kaplun, M. Dobson, and G. Tzivion Raf kinases: function, regulation and role in human cancer Biochim. Biophys. Acta - Mol. Cell Res. 1773 2007 1196 1212
6. G. Galabova-Kovacs, A. Kolbus, D. Matzen, K. Meissl, D. Piazzolla, C. Rubiolo, K. Steinitz, and M. Baccarini ERK and beyond: insights from B-Raf and Raf-1 conditional knockouts Cell Cycle 5 2006 1514 1518
7. C. Wellbrock, M. Karasarides, and R. Marais The RAF proteins take centre stage Nat. Rev. Mol. Cell Biol. 5 2004 875 885
8. L. Wojnowski, L.F. Stancato, A.C. Larner, U.R. Rapp, and A. Zimmer Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis Mech. Dev. 91 2000 97 104
9. M. Mikula et al. Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene EMBO J. 20 2001 1952 1962
10. M. Huser et al. MEK kinase activity is not necessary for Raf-1 function EMBO J. 20 2001 1940 1951
11. C.A. Pritchard, L. Hayes, L. Wojnowski, A. Zimmer, R.M. Marais, and J.C. Norman B-Raf acts via the ROCKII/LIMK/cofilin pathway to maintain actin stress fibers in fibroblasts Mol. Cell. Biol. 24 2004 5937 5952
12. K. Mercer, A. Chiloeches, M. Huser, M. Kiernan, R. Marais, and C. Pritchard ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf Oncogene 21 2002 347 355
13. M.J. Garnett, and R. Marais Guilty as charged: B-RAF is a human oncogene Cancer Cell 6 2004 313 319
14. P.T. Wan et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 2004 855 867
15. R. Wimmer, and M. Baccarini Partner exchange: protein-protein interactions in the Raf pathway Trends Biochem. Sci. 35 2010 660 668
16. D. Matallanas, M. Birtwistle, D. Romano, A. Zebisch, J. Rauch, A. von Kriegsheim, and W. Kolch Raf family kinases: old dogs have learned new tricks Genes Cancer 2 2011 232 260
17. M.M. McKay, A.K. Freeman, and D.K. Morrison Complexity in KSR function revealed by Raf inhibitor and KSR structure studies Small GTPases 2 2011 276 281
18. C.K. Weber, J.R. Slupsky, H.A. Kalmes, and U.R. Rapp Active Ras induces heterodimerization of cRaf and BRaf Cancer Res. 61 2001 3595 3598
19. M.J. Garnett, S. Rana, H. Paterson, D. Barford, and R. Marais Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization Mol. Cell 20 2005 963 969
20. L.K. Rushworth, A.D. Hindley, E. O'Neill, and W. Kolch Regulation and role of Raf-1/B-Raf heterodimerization Mol. Cell. Biol. 26 2006 2262 2272
21. T. Rajakulendran, M. Sahmi, M. Lefrancois, F. Sicheri, and M. Therrien A dimerization-dependent mechanism drives RAF catalytic activation Nature 461 2009 542 545
22. J. Hu et al. Allosteric activation of functionally asymmetric RAF kinase dimers Cell 154 2013 1036 1046
23. A.K. Freeman, D.A. Ritt, and D.K. Morrison Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling Mol. Cell 49 2013 751 758
24. S.J. Heidorn et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Cell 140 2010 209 221
25. C.S. Mason, C.J. Springer, R.G. Cooper, G. Superti-Furga, C.J. Marshall, and R. Marais Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation EMBO J. 18 1999 2137 2148
26. D.T. Leicht, V. Balan, J. Zhu, A. Kaplun, A. Bronisz, A. Rana, and G. Tzivion MEK-1 activates C-Raf through a Ras-independent mechanism Biochim. Biophys. Acta 1833 2013 976 986
27. D.F. Brennan, A.C. Dar, N.T. Hertz, W.C. Chao, A.L. Burlingame, K.M. Shokat, and D. Barford A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK Nature 472 2011 366 369
28. M.M. McKay, D.A. Ritt, and D.K. Morrison RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling Curr. Biol. 21 2011 563 568
29. M. Roring et al. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling EMBO J. 31 2012 2629 2647
30. P.I. Poulikakos et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) Nature 480 2011 387 390
31. F.A. Karreth, G.M. DeNicola, S.P. Winter, and D.A. Tuveson C-Raf inhibits MAPK activation and transformation by B-Raf(V600E) Mol. Cell 36 2009 477 486
32. L. Wojnowski, A.M. Zimmer, T.W. Beck, H. Hahn, R. Bernal, U.R. Rapp, and A. Zimmer Endothelial apoptosis in Braf-deficient mice Nat. Genet. 16 1997 293 297
33. C.A. Pritchard, L. Bolin, R. Slattery, R. Murray, and M. McMahon Post-natal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene Curr. Biol. 6 1996 614 617
34. G. Galabova-Kovacs, D. Matzen, D. Piazzolla, K. Meissl, T. Plyushch, A.P. Chen, A. Silva, and M. Baccarini Essential role of B-Raf in ERK activation during extraembryonic development Proc. Natl. Acad. Sci. USA 103 2006 1325 1330
35. G. Galabova-Kovacs et al. Essential role of B-Raf in oligodendrocyte maturation and myelination during postnatal central nervous system development J. Cell Biol. 180 2008 947 955
36. F. Kern, E. Doma, C. Rupp, T. Niault, and M. Baccarini Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis Oncogene 32 2013 2483 2492
37. I. Sobczak, G. Galabova-Kovacs, I. Sadzak, A. Kren, G. Christofori, and M. Baccarini B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic beta-cell carcinogenesis Oncogene 27 2008 4779 4787
38. J.F. Ohren et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition Nat. Struct. Mol. Biol. 11 2004 1192 1197
39. F. Catalanotti, G. Reyes, V. Jesenberger, G. Galabova-Kovacs, R. de Matos Simoes, O. Carugo, and M. Baccarini A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal Nat. Struct. Mol. Biol. 16 2009 294 303
40. S. Giroux et al. Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta Curr. Biol. 9 1999 369 372
41. L.F. Belanger et al. Mek2 is dispensable for mouse growth and development Mol. Cell. Biol. 23 2003 4778 4787
42. J.L. Wilsbacher, Y.C. Juang, A.V. Khokhlatchev, E. Gallagher, D. Binns, E.J. Goldsmith, and M.H. Cobb Characterization of mitogen-activated protein kinase (MAPK) dimers Biochemistry 45 2006 13175 13182
43. B. Casar, A. Pinto, and P. Crespo Essential role of ERK dimers in the activation of cytoplasmic but not nuclear substrates by ERK-scaffold complexes Mol. Cell 31 2008 708 721
44. M.K. Saba-El-Leil, F.D. Vella, B. Vernay, L. Voisin, L. Chen, N. Labrecque, S.L. Ang, and S. Meloche An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development EMBO Rep. 4 2003 964 968
45. G. Pages, S. Guerin, D. Grall, F. Bonino, A. Smith, F. Anjuere, P. Auberger, and J. Pouyssegur Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice Science 286 1999 1374 1377
46. C. Mazzucchelli et al. Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory Neuron 34 2002 807 820
47. F. Bost et al. The extracellular signal-regulated kinase isoform ERK1 is specifically required for in vitro and in vivo adipogenesis Diabetes 54 2005 402 411
48. R. Lefloch, J. Pouyssegur, and P. Lenormand Single and combined silencing of ERK1 and ERK2 reveals their positive contribution to growth signaling depending on their expression levels Mol. Cell. Biol. 28 2008 511 527
49. D.S. Lidke et al. ERK nuclear translocation is dimerization-independent but controlled by the rate of phosphorylation J. Biol. Chem. 285 2010 3092 3102
50. B. Casar, A. Pinto, and P. Crespo ERK dimers and scaffold proteins: unexpected partners for a forgotten (cytoplasmic) task Cell Cycle 8 2009 1007 1013
51. L. Buday, P.H. Warne, and J. Downward Downregulation of the Ras activation pathway by MAP kinase phosphorylation of Sos Oncogene 11 1995 1327 1331
52. C. Dong, S.B. Waters, K.H. Holt, and J.E. Pessin SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways J. Biol. Chem. 271 1996 6328 6332
53. M.K. Dougherty et al. Regulation of Raf-1 by direct feedback phosphorylation Mol. Cell 17 2005 215 224
54. O.E. Sturm et al. The mammalian MAPK/ERK pathway exhibits properties of a negative feedback amplifier Sci. Signal. 3 2010 ra90
55. R. Fritsche-Guenther et al. Strong negative feedback from Erk to Raf confers robustness to MAPK signalling Mol. Syst. Biol. 7 2011 489
56. T. Brummer, H. Naegele, M. Reth, and Y. Misawa Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf Oncogene 22 2003 8823 8834
57. D.A. Ritt, D.M. Monson, S.I. Specht, and D.K. Morrison Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling Mol. Cell. Biol. 30 2010 806 819
58. K.P. Hoeflich et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models Clin. Cancer Res. 15 2009 4649 4664
59. S. Ussar, and T. Voss MEK1 and MEK2, different regulators of the G1/S transition J. Biol. Chem. 279 2004 43861 43869
60. K. Zmajkovicova, V. Jesenberger, F. Catalanotti, C. Baumgartner, G. Reyes, and M. Baccarini MEK1 is required for PTEN membrane recruitment, AKT regulation, and the maintenance of peripheral tolerance Mol. Cell 50 2013 43 55
61. J.J. Hornberg, B. Binder, F.J. Bruggeman, B. Schoeberl, R. Heinrich, and H.V. Westerhoff Control of MAPK signalling: from complexity to what really matters Oncogene 24 2005 5533 5542
62. J.J. Hornberg, F.J. Bruggeman, B. Binder, C.R. Geest, A.J. de Vaate, J. Lankelma, R. Heinrich, and H.V. Westerhoff Principles behind the multifarious control of signal transduction. ERK phosphorylation and kinase/phosphatase control FEBS J. 272 2005 244 258
63. V. Janssens, J. Goris, and C. Van Hoof PP2A: the expected tumor suppressor Curr. Opin. Genet. Dev. 15 2005 34 41
64. D.A. Wassarman, N.M. Solomon, H.C. Chang, F.D. Karim, M. Therrien, and G.M. Rubin Protein phosphatase 2A positively and negatively regulates Ras1- mediated photoreceptor development in Drosophila Genes Dev. 10 1996 272 278
65. D. Abraham et al. Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation J. Biol. Chem. 275 2000 22300 22304
66. M. Jaumot, and J.F. Hancock Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions Oncogene 20 2001 3949 3958
67. M. Kubicek, M. Pacher, D. Abraham, K. Podar, M. Eulitz, and M. Baccarini Dephosphorylation of Ser-259 regulates Raf-1 membrane association J. Biol. Chem. 277 2002 7913 7919
68. S. Ory, M. Zhou, T.P. Conrads, T.D. Veenstra, and D.K. Morrison Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites Curr. Biol. 13 2003 1356 1364
69. D.G. Adams, R.L. Coffee Jr., H. Zhang, S. Pelech, S. Strack, and B.E. Wadzinski Positive regulation of Raf1-MEK1/2-ERK1/2 signaling by protein serine/threonine phosphatase 2A holoenzymes J. Biol. Chem. 280 2005 42644 42654
70. P. Rodriguez-Viciana, J. Oses-Prieto, A. Burlingame, M. Fried, and F. McCormick A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity Mol. Cell 22 2006 217 230
71. M. Hekman, A. Fischer, L.P. Wennogle, Y.K. Wang, S.L. Campbell, and U.R. Rapp Novel C-Raf phosphorylation sites: serine 296 and 301 participate in Raf regulation FEBS Lett. 579 2005 464 468
72. V. Balan et al. Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase Mol. Biol. Cell 17 2006 1141 1153
73. S. Ugi, T. Imamura, W. Ricketts, and J.M. Olefsky Protein phosphatase 2A forms a molecular complex with Shc and regulates Shc tyrosine phosphorylation and downstream mitogenic signaling Mol. Cell. Biol. 22 2002 2375 2387
74. E. Sontag, S. Fedorov, C. Kamibayashi, D. Robbins, M. Cobb, and M. Mumby The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation Cell 75 1993 887 897
75. S. Kins, P. Kurosinski, R.M. Nitsch, and J. Gotz Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice Am. J. Pathol. 163 2003 833 843
76. A.M. Silverstein, C.A. Barrow, A.J. Davis, and M.C. Mumby Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits Proc. Natl. Acad. Sci. USA 99 2002 4221 4226
77. A. von Kriegsheim, A. Pitt, G.J. Grindlay, W. Kolch, and A.S. Dhillon Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5 Nat. Cell Biol. 8 2006 1011 1016
78. C.J. Caunt, and S.M. Keyse Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling FEBS J. 280 2013 489 504
79. A. Brunet, D. Roux, P. Lenormand, S. Dowd, S. Keyse, and J. Pouyssegur Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry EMBO J. 18 1999 664 674
80. M. Karlsson, J. Mathers, R.J. Dickinson, M. Mandl, and S.M. Keyse Both nuclear-cytoplasmic shuttling of the dual specificity phosphatase MKP-3 and its ability to anchor MAP kinase in the cytoplasm are mediated by a conserved nuclear export signal J. Biol. Chem. 279 2004 41882 41891
81. J. Chen, K. Fujii, L. Zhang, T. Roberts, and H. Fu Raf-1 promotes cell survival by antagonizing apoptosis signal- regulating kinase 1 through a MEK-ERK independent mechanism Proc. Natl. Acad. Sci. USA 98 2001 7783 7788
82. E. O'Neill, and W. Kolch Conferring specificity on the ubiquitous Raf/MEK signalling pathway Br. J. Cancer 90 2004 283 288
83. D. Matallanas et al. RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein Mol. Cell 27 2007 962 975
84. K. Riento, and A.J. Ridley Rocks: multifunctional kinases in cell behaviour Nat. Rev. Mol. Cell Biol. 4 2003 446 456
85. K. Ehrenreiter, D. Piazzolla, V. Velamoor, I. Sobczak, J.V. Small, J. Takeda, T. Leung, and M. Baccarini Raf-1 regulates Rho signaling and cell migration J. Cell Biol. 168 2005 955 964
86. K. Ehrenreiter, F. Kern, V. Velamoor, K. Meissl, G. Galabova-Kovacs, M. Sibilia, and M. Baccarini Raf-1 addiction in Ras-induced skin carcinogenesis Cancer Cell 16 2009 149 160
87. R. Wimmer, B. Cseh, B. Maier, K. Scherrer, and M. Baccarini Angiogenic sprouting requires the fine tuning of endothelial cell cohesion by the Raf-1/Rok-alpha complex Dev. Cell 22 2012 158 171
88. D. Piazzolla, K. Meissl, L. Kucerova, C. Rubiolo, and M. Baccarini Raf-1 sets the threshold of Fas sensitivity by modulating Rok-{alpha} signaling J. Cell Biol. 171 2005 1013 1022
89. F.A. Karreth, K.K. Frese, G.M. Denicola, M. Baccarini, and D.A. Tuveson C-Raf is required for the initiation of lung cancer by K-Ras Cancer Discov. 1 2011 128 136
90. R.B. Blasco, S. Francoz, D. Santamaria, M. Canamero, P. Dubus, J. Charron, M. Baccarini, and M. Barbacid C-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma Cancer Cell 19 2011 652 663
91. J. Rauch, E. O'Neill, B. Mack, C. Matthias, M. Munz, W. Kolch, and O. Gires Heterogeneous nuclear ribonucleoprotein H blocks MST2-mediated apoptosis in cancer cells by regulating A-Raf transcription Cancer Res. 70 2010 1679 1688
92. E. Doma, C. Rupp, A. Varga, F. Kern, B. Riegler, and M. Baccarini Skin tumorigenesis stimulated by Raf inhibitors relies upon Raf functions that are dependent and independent of ERK Cancer Res. 73 2013 6926 6937
93. P.B. Chapman et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N. Engl. J. Med. 364 2011 2507 2516
94. K.T. Flaherty et al. Inhibition of mutated, activated BRAF in metastatic melanoma N. Engl. J. Med. 363 2010 809 819
95. J.A. Sosman et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N. Engl. J. Med. 366 2012 707 714
96. J.T. Lee et al. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas Pigment Cell Melanoma Res. 23 2010 820 827
97. E.W. Joseph et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner Proc. Natl. Acad. Sci. USA 107 2010 14903 14908
98. A.D. Ballantyne, and K.P. Garnock-Jones Dabrafenib: first global approval Drugs 73 2013 1367 1376
99. A. Hauschild et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 2012 358 365
100. G. Bollag et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 467 2010 596 599
101. G.T. Gibney, and J.S. Zager Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies Expert Opin. Drug Metabol. Toxicol. 9 2013 893 899
102. H. Wong, M. Belvin, S. Herter, K.P. Hoeflich, L.J. Murray, L. Wong, and E.F. Choo Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden- 5-yl]-3-(pyridine-4-yl)-1H-pyraz ol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy J. Pharmacol. Exp. Ther. 329 2009 360 367
103. T. Yamaguchi, R. Kakefuda, N. Tajima, Y. Sowa, and T. Sakai Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo Int. J. Oncol. 39 2011 23 31
104. H. Huynh, K.C. Soo, P.K. Chow, and E. Tran Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma Mol. Cancer Ther. 6 2007 138 146
105. S.D. Barrett et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901 Bioorg. Med. Chem. Lett. 18 2008 6501 6504
106. N. Ishii et al. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity Cancer Res. 73 2013 4050 4060
107. G. Hatzivassiliou et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Nature 464 2010 431 435
108. P.I. Poulikakos, C. Zhang, G. Bollag, K.M. Shokat, and N. Rosen RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464 2010 427 430
109. P.A. Oberholzer et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors J. Clin. Oncol. 30 2012 316 321
110. F. Su et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors N. Engl. J. Med. 366 2012 207 215
111. K.P. Hoeflich et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression Cancer Res. 69 2009 3042 3051
112. T. Niault et al. From autoinhibition to inhibition in trans: the Raf-1 regulatory domain inhibits Rok-alpha kinase activity J. Cell Biol. 187 2009 335 342
113. M. Holderfield et al. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation Cancer Cell 23 2013 594 602
114. C. Sun et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma Nature 508 2014 118 122
115. R. Nazarian et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 2010 973 977
116. J. Villanueva et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K Cancer Cell 18 2010 683 695
117. R. Straussman et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Nature 487 2012 500 504
118. T.R. Wilson et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors Nature 487 2012 505 509
119. P. Lito et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas Cancer Cell 22 2012 668 682
120. A. Prahallad et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature 483 2012 100 103
121. R.B. Corcoran et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib Cancer Discov. 2 2012 227 235
122. F. Su et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation Cancer Res. 72 2012 969 978
123. S. Wee et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers Cancer Res. 69 2009 4286 4293
124. N. Wagle et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling J. Clin. Oncol. 29 2011 3085 3096
125. C.M. Emery et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition Proc. Natl. Acad. Sci. USA 106 2009 20411 20416
126. H. Shi et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance Nat. Commun. 3 2012 724
127. C. Montagut et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma Cancer Res. 68 2008 4853 4861
128. C.M. Johannessen et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 468 2010 968 972
129. C.M. Johannessen et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition Nature 504 2013 138 142
130. J.R. Infante et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial Lancet Oncol. 13 2012 773 781
131. D.B. Solit et al. BRAF mutation predicts sensitivity to MEK inhibition Nature 439 2006 358 362
132. P. Lito et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors Cancer Cell 25 2014 697 710
133. G. Hatzivassiliou et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers Nature 501 2013 232 236
134. C.A. Pratilas, B.S. Taylor, Q. Ye, A. Viale, C. Sander, D.B. Solit, and N. Rosen (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway Proc. Natl. Acad. Sci. USA 106 2009 4519 4524
135. A.G. Gilmartin et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition Clin. Cancer Res. 17 2011 989 1000
136. K.T. Flaherty et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations New Engl. J. Med. 367 2012 1694 1703
137. B. Sanchez-Laorden et al. BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling Sci. Signal. 7 2014 ra30
138. S. Turajlic, Z. Ali, N. Yousaf, and J. Larkin Phase I/II RAF kinase inhibitors in cancer therapy Expert Opin. Investig. Drugs 22 2013 739 749
139. K. Garber Melanoma combination therapies ward off tumor resistance Nat. Biotechnol. 31 2013 666 668
140. M. Das Thakur et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance Nature 494 2013 251 255
141. A.C. Seghers, S. Wilgenhof, C. Lebbe, and B. Neyns Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor Melanoma Res. 22 2012 466 472